BOSTON– SOTIO Biotech, a clinical-stage biopharmaceutical company backed by PPF Group, has announced the appointments of Amy Jensen-Smith, Ph.D., as Chief Scientific Officer and Ulrich Moebius, Ph.D., as Chief Development Officer. These leadership changes are aimed at advancing the company’s pipeline of antibody-drug conjugates (ADCs) and immunotherapies targeting difficult-to-treat solid tumors.
Dr. Jensen-Smith, who previously served as Vice President and Head of Discovery at SOTIO US, has been instrumental in shaping the company’s scientific direction since joining in 2020. She led the discovery and development of key preclinical ADC candidates, including SOT106 and SOT109, which have shown strong efficacy and safety profiles in mesenchymal tumors and colorectal cancer, respectively. She also helped guide the company’s focus on BOXR-based technologies and was responsible for filing multiple provisional patents. In her new role as Chief Scientific Officer, she will oversee all global discovery and preclinical research efforts.
Prior to her time at SOTIO, Dr. Jensen-Smith held leadership roles at bluebird bio, where she advanced CAR and TCR T cell therapy programs and managed strategic external partnerships. She earned her B.S. in biochemistry and molecular biology from the University of Massachusetts Amherst and a Ph.D. in physiology from Dartmouth College. She completed postdoctoral training at the National Cancer Institute and was a Presidential Post-Doctoral Fellow at Novartis Institutes for BioMedical Research (NIBR).
Dr. Moebius, who served as SOTIO’s Chief of Preclinical Development from 2017 to 2024, now steps into the role of Chief Development Officer. He brings more than 25 years of experience guiding drug candidates from early research through nonclinical development and into the clinic. During his tenure at SOTIO, he led IND-enabling work across multiple therapeutic platforms and played a key role in advancing several oncology and autoimmune programs.
Dr. Moebius previously held leadership roles at MediGene, Morphosys, and Pieris, overseeing R&D strategy, nonclinical development, and project management. He earned his Ph.D. in immunology from Johannes Gutenberg University of Mainz and conducted over a decade of academic research at the German Cancer Research Center (DKFZ) and Dana-Farber Cancer Institute, specializing in immune cell function and immuno-oncology.
“We are fortunate to have such exceptional scientific talent within SOTIO to lead the continued progress and expansion of our portfolio of next-generation ADCs and immunotherapies,” said Radek Spisek, Chief Executive Officer of SOTIO. “Amy’s proven record of scientific excellence and innovation has been instrumental in advancing our pipeline, and Ulrich’s leadership in development makes him ideally suited for this new role. Their deep expertise and history with the company give me full confidence they will help drive our mission to deliver transformative therapies for patients.”
